Publicacións en colaboración con investigadores/as de Hospital Clinic Barcelona (18)

2024

  1. Indicators to evaluate quality of care in head and neck cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 5, pp. 1089-1097

2022

  1. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer

    Oral Oncology, Vol. 134

2021

  1. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 764-772

2018

  1. Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii612

  2. Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice

    Clinical and Translational Oncology, Vol. 20, Núm. 7, pp. 862-869

  3. Oncologist’s knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study

    Clinical and Translational Oncology, Vol. 20, Núm. 5, pp. 613-618

2017

  1. Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study

    International Journal of Radiation Oncology Biology Physics, Vol. 97, Núm. 3, pp. 473-480

  2. GEIS-21: A multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: A report from the Spanish sarcoma group (GEIS)

    British Journal of Cancer, Vol. 117, Núm. 6, pp. 767-774

2016

  1. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients with Unresectable Squamous Cell Carcinoma of the Head and Neck

    International Journal of Radiation Oncology Biology Physics, Vol. 94, Núm. 2, pp. 289-296

  2. A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia

    British Journal of Cancer, Vol. 114, Núm. 11, pp. 1191-1198

2014

  1. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer

    Annals of Oncology, Vol. 25, Núm. 1, pp. 216-225

  2. Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists

    Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 914-920

2012

  1. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck

    Annals of Oncology, Vol. 23, Núm. 4, pp. 1016-1022

2009

  1. Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients

    Clinical and Translational Oncology, Vol. 11, Núm. 11, pp. 727-736

2006

  1. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia

    Journal of the National Cancer Institute, Vol. 98, Núm. 4, pp. 273-284

2005

  1. Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5- fluorouracil for locally advanced squamous cell carcinoma of the head and neck: A randomised phase II study

    European Journal of Cancer, Vol. 41, Núm. 9, pp. 1254-1260

2003

  1. Quimioprevención del cáncer

    Medicina Clinica

1995

  1. A phase II trial of weekly high dose continuous infusion 5‐fluorouracil plus oral leucovorin in patients with advanced colorectal cancer

    Cancer, Vol. 76, Núm. 4, pp. 559-563